Emphascience
Private pharmaceutical company focused on developing reformulated versions of approved drugs to address unmet medical needs (pain, oncology, infections and other serious diseases). Activities emphasize formulation chemistry, stability and delivery optimization to enable new therapeutic uses, improved safety, ease-of-use, and faster market entry through regulatory pathways appropriate for reformulations.
Industries
Nr. of Employees
small (1-50)
Emphascience
Pittsford, New York, United States, North America
Products
Ready-to-use injectable formulations
Sterile injectable formulations designed to be administered without on-site compounding or reconstitution.
Extended-release intramuscular injections
Sustained-release depot injectables intended to enable less frequent dosing (e.g., monthly administration).
Ready-to-dilute intravenous infusion formulations
IV infusion products designed for simplified preparation and administration in clinical settings.
Topical and oral dosage form reformulations
Topical gels and oral dosage forms reformulated to improve usability, onset of action, or to remove dosing restrictions related to food or timing.
Orally Administered Fulvestrant
An orally administered fulvestrant capsule designed with adequate bioavailability and shelf-life as a potential alternative to long-acting intramuscular depot injections for breast cancer.
Stable Epinephrine (Adrenaline) Injection Without Sulfite
A sterile epinephrine injection that does not contain sodium metabisulfite while offering improved stability for longer storage and usage periods.
Ready-to-use injectable formulations
Sterile injectable formulations designed to be administered without on-site compounding or reconstitution.
Extended-release intramuscular injections
Sustained-release depot injectables intended to enable less frequent dosing (e.g., monthly administration).
Ready-to-dilute intravenous infusion formulations
IV infusion products designed for simplified preparation and administration in clinical settings.
Topical and oral dosage form reformulations
Topical gels and oral dosage forms reformulated to improve usability, onset of action, or to remove dosing restrictions related to food or timing.
Orally Administered Fulvestrant
An orally administered fulvestrant capsule designed with adequate bioavailability and shelf-life as a potential alternative to long-acting intramuscular depot injections for breast cancer.
Stable Epinephrine (Adrenaline) Injection Without Sulfite
A sterile epinephrine injection that does not contain sodium metabisulfite while offering improved stability for longer storage and usage periods.
Services
Concept generation and formulation design for approved drugs to improve stability, delivery and therapeutic scope.
Development of ready-to-use injections, ready-to-dilute IV infusions, and heat-sterilized sterile formats aimed at improving safety and ease of administration.
Formulation and excipient strategies to improve solubility and systemic availability of poorly soluble drugs.
Regulatory planning and preparation aligned with filing pathways appropriate for reformulated products, including regulatory approaches that leverage existing data.
Commercialization support through out-licensing programs to marketing partners and collaboration on clinical proof-of-concept.
Concept generation and formulation design for approved drugs to improve stability, delivery and therapeutic scope.
Development of ready-to-use injections, ready-to-dilute IV infusions, and heat-sterilized sterile formats aimed at improving safety and ease of administration.
Formulation and excipient strategies to improve solubility and systemic availability of poorly soluble drugs.
Regulatory planning and preparation aligned with filing pathways appropriate for reformulated products, including regulatory approaches that leverage existing data.
Commercialization support through out-licensing programs to marketing partners and collaboration on clinical proof-of-concept.
Expertise Areas
- Drug formulation and delivery
- Parenteral (sterile) product development
- Solubility and bioavailability enhancement
- Sustained-release and depot formulation development
Key Technologies
- Formulation chemistry
- Parenteral sterile formulation
- Solubility enhancement technologies
- Sustained-release depot technologies
News & Updates
Participation at the 28th Annual ROTH Conference (April 16, 2016).
Press release announcing plans to showcase pipeline at an R&D day.
Participation at the 28th Annual ROTH Conference (April 16, 2016).
Press release announcing plans to showcase pipeline at an R&D day.